糖尿病と臨床実践のジャーナル

抽象的な

Geographical Access Disparities to Diabetic Eye Disease Clinical Trials in the United States

Sandy Maghirie

Geographical access disparities to diabetic eye disease clinical trials in the United States contribute to unequal healthcare opportunities and outcomes. This article examines the challenges faced by individuals in different regions and proposes potential solutions to address these disparities. Diabetic eye disease, including retinopathy and macular edema, imposes a significant burden on public health. Clinical trials are crucial for developing effective treatments, but access to these trials varies geographically. Rural areas experience limited trial availability due to a concentration of trials in urban centers. Additionally, socioeconomic factors, including low-income communities and minority populations, further contribute to access disparities. To overcome these challenges, telemedicine and remote trial methodologies can bridge the gap between trial sites and remote areas, facilitating participation. Collaborative efforts between research institutions, healthcare organizations, and community outreach programs can improve awareness and education about clinical trials. Policymakers and funding agencies should prioritize addressing access disparities by supporting trial infrastructure, providing travel assistance, and implementing equitable distribution policies. By addressing these geographical access disparities, the United States can ensure that all individuals, regardless of their location or socioeconomic status, have equal opportunities to participate in diabetic eye disease clinical trials, leading to improved treatments and management strategies.